A Phase 2/3 interventional study of DBS Activa PC systems Medtronic and DBS, Activa PC systems Medtronic in Bipolar Disorder, sponsored by University Hospital, Bonn. Withdrawn at 1 site in Germany. Open to participants aged 20 Years to 70 Years. Per ClinicalTrials.gov, last updated 2018-08-07.
Sponsored by University Hospital, Bonn · Phase 2/3, Interventional, and Treatment
Hypothesis to be tested:
Bilateral Deep Brain Stimulation to the Nucleus Accumbens is associated with clinically and statistically significant improvement in patients with treatment resistant bipolar disorder.
Overall Objective:
The aim in this interdisciplinary, psychiatric-neurosurgical project is to evaluate safety and efficacy of bilateral Deep Brain Stimulation to the Nucleus Accumbens (NAcc) using the Medtronic Activa RC Neurostimulator in patients with treatment resistant Bipolar Disorder.
1,601 studies on the registry are indexed under Bipolar Disorder; 254 are open to participants now.
Browse Bipolar Disorder studies →University Hospital, Bonn is the lead sponsor of 154 studies on the registry; 30 are open to participants now.
Counted across the registry records on this site, refreshed daily.
-If currently in psychotherapy, a patient must have been in this therapy for at least six months and continue to attend scheduled visits at no greater or lesser frequency than during the last three months. -
Exclusion Criteria:
Device: DBS Activa PC systems Medtronic
Device: DBS, Activa PC systems Medtronic
130Hz, 90us pulsewidth, 4V Amplitude
30Hz, 90us pulsewidth, 4V Amplitude
Depression Severity rated with Montgomery Asberg Depression Scale (MADRS)
The Montgomery-Åsberg Depression Rating Scale (abbreviated MADRS) is a ten-item diagnostic questionnaire which psychiatrists use to measure the severity of depressive episodes in patients with mood disorders. It was designed in 1979 by British and Swedish researchers as an adjunct to the Hamilton Rating Scale for Depression (HAMD) which would be more sensitive to the changes brought on by antidepressants and other forms of treatment than the Hamilton Scale is.
Time frame: 12 month after DBS stimulation onset
Young Mania Rating Scale (YMRS)
One of the most frequently used rating scales to assess manic symptoms. The scale has 11 items and is based on the patient's subjective report of his or her clinical condition over the previous 48 hours. This scale will be used to assess the development of manic symptoms over time, mainly in order to assess treatment emergent manic symptoms.
Time frame: 12 month after DBS stimulation onset
Depression Severity rated with Hamilton Depression Rating Scale (HDRS24)
The Hamilton Rating Scale for Depression (HRSD), also known as the Hamilton Depression Rating Scale (HDRS) or abbreviated to HAM-D, is a multiple choice questionnaire that clinicians may use to rate the severity of a patient's major depression. The questionnaire rates the severity of symptoms observed in depression such as low mood, insomnia, agitation, anxiety and weight loss. The questionnaire is presently one of the most commonly used scales for rating depression in medical research.
Time frame: 12 month after DBS stimulation onset
Adverse Event Schedule
Adverse events induced by the Stimulation will be recorded during the study using a structured questionnaire. 12 months after stimulation onset results will be compiled and rated as being due to DBS or not.
Time frame: 12 month after DBS stimulation onset
Comprehensive neuropsychological test battery
* General cognitive functions (Mini-Mental State Examination) * Attention (d2 attention-burden test) * Learning and memory tests covering verbal and visual spatial learning, memory and working memory (Verbal Learning and Memory Test, Rey Visual Design Learning Test,Wechsler Memory Scale) * language (HAWIE lexis tests, HAWIE finding similarities) * Executive functions (Trail Making Tests, Five-Point Test, and the Stroop test) * Visual perception (Hooper Visual Organization Test)
Time frame: 12 month after DBS stimulation onset
This study is withdrawn, as verified in Aug 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Hospital, Bonn